Burosumab is a recombinant human monoclonal antibody (IgG1) that binds to FGF23 and inhibits its activity, but to date, it is only indicated for XLH-linked hypophosphatemia; it is not indicated for CKD due to the risk of severe hyperphosphatemia that patients may experience [58]. The gene discussed is FGF23; the disease is hyperphosphatemia.